Bioequivalency, Dermatology and Development - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioequivalency

Dermatology

Development

SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis

The Pharma Data

AUGUST 9, 2021

Food and Drug Administration (FDA) approved SKYRIZI 150 mg in April based on data from three clinical trials showing the single-dose SKYRIZI 150 mg injection was bioequivalent, working the same as two injections of SKYRIZI 75 mg per dose with a consistent efficacy and safety profile. .” The U.S.

Bioequivalency

Bioequivalency Vaccination Vaccine Medicine

Topical products: Aiming for quality, simplicity, and cost-efficiency in their development, scale-up, and manufacturing

Pharmaceutical Technology

JANUARY 6, 2023

The preparation of a semi-solid dosage form – from formulation and development, to scale-up, commercial manufacturing, and packaging – should ideally take place under one roof in a contiguous, end-to-end workflow to avoid unnecessary equipment and process changes. Optimising development and scale-up. Particle distribution. Grittiness.

Production

Production Manufacturing Development Bioequivalency

SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis

Topical products: Aiming for quality, simplicity, and cost-efficiency in their development, scale-up, and manufacturing

Stay Connected